Follow
I am an investor with a background in biotechnology and genetics. My Ph.D. education and professional experience are focused on genetics, stem cells, CRISPR, next generation sequencing and gene therapy. My investments and investment ideas are focused on long plays on under-appreciated/revolutionary products at the cutting edge of science with a few short ideas based on concerns related to the scientific underpinnings of a select number of companies.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of SRPT, REGN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.